Cargando…
Symposium on Clinical Pharmacology : [papers] : held at the Hotel Robert Mayer, Jacksonville, Florida, March 12-13, 1973 /
Symposium on Clinical Pharmacology reviews advances in clinical pharmacology, with emphasis on how to materially improve the efficacy of cancer chemotherapy. Topics range from absorption, protein binding, distribution, and excretion of antineoplastic drugs to factors affecting the biotransformation...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores Corporativos: | , |
| Otros Autores: | , , |
| Formato: | Electrónico Congresos, conferencias eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
Pergamon Press,
1975.
|
| Colección: | Biochemical pharmacology : Supplement ;
1974, no. 2. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn610213939 | ||
| 003 | OCoLC | ||
| 005 | 20231117033113.0 | ||
| 006 | m o d | ||
| 007 | cr bn||||||abp | ||
| 007 | cr bn||||||ada | ||
| 008 | 100429s1975 nyua ob 100 0 eng d | ||
| 040 | |a OCLCE |b eng |e pn |c OCLCE |d OCLCQ |d UIU |d OCLCQ |d OCLCF |d OCLCO |d N$T |d EBLCP |d OCLCO |d OCL |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d YDXCP |d OCLCA |d STF |d OCLCO |d OCLCA |d OCLCQ |d OCLCO |d COM |d OCLCO |d OCL |d OCLCQ |d OCLCO | ||
| 019 | |a 896795279 |a 948744521 |a 974615928 | ||
| 020 | |a 9781483139401 |q (electronic bk.) | ||
| 020 | |a 1483139409 |q (electronic bk.) | ||
| 020 | |z 0080189504 | ||
| 020 | |z 9780080189505 | ||
| 020 | |z 0080189490 |q (pbk.) | ||
| 020 | |z 9780080189499 |q (pbk.) | ||
| 035 | |a (OCoLC)610213939 |z (OCoLC)896795279 |z (OCoLC)948744521 |z (OCoLC)974615928 | ||
| 042 | |a dlr | ||
| 050 | 4 | |a RC271.C5 |b S93 1973 | |
| 060 | 4 | |a W1 |b B1622 v.23 1975 suppl. no.2 | |
| 060 | 4 | |a QZ 267 |b S989s 1973 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.9/94/061 |
| 111 | 2 | |a Symposium on Clinical Pharmacology |d (1973 : |c Jacksonville, Fla.) | |
| 245 | 1 | 0 | |a Symposium on Clinical Pharmacology : |b [papers] : held at the Hotel Robert Mayer, Jacksonville, Florida, March 12-13, 1973 / |c sponsored by the National Cancer Institute, Cancer Clinical Investigation Review Committee, Clinical Investigation Branch ; [edited by] Symposium Committee, William A. Creasey, Montague Lane, Alan C. Sartorelli, Chairman. |
| 260 | |a New York : |b Pergamon Press, |c 1975. | ||
| 300 | |a 1 online resource (iv, 236 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Biochemical pharmacology : Supplement ; |v v. 23, 1974, no. 2 | |
| 504 | |a Includes bibliographical references. | ||
| 506 | |3 Use copy |f Restrictions unspecified |2 star |5 MiAaHDL | ||
| 533 | |a Electronic reproduction. |b [Place of publication not identified] : |c HathiTrust Digital Library, |d 2010. |5 MiAaHDL | ||
| 538 | |a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. |u http://purl.oclc.org/DLF/benchrepro0212 |5 MiAaHDL | ||
| 583 | 1 | |a digitized |c 2010 |h HathiTrust Digital Library |l committed to preserve |2 pda |5 MiAaHDL | |
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Front Cover; Symposium on Clinical Pharmacology; Copyright Page; Table of Contents; INTRODUCTORY REMARKS; PART 1: PHARMACOLOGICAL FACTORS IN DRUG ACTION; PART 2: FACTORS INFLUENCING DRUG SELECTIVITY; PART 3: MECHANISMS OF CLINICAL DRUG RESISTANCE; PART 4: COMBINATION CHEMOTHERAPY; PART 5: NEW INFORMATION ON MECHANISMS OF DRUG ACTION; CHAPTER 1. PHARMACOKINETICS AND DRUG EFFECT; Classical pharmacokinetic models; Physiological pharmacokinetic model; Methotrexate kinetics and effect; REFERENCES; CHAPTER 2. ABSORPTION, PROTEIN BINDING, DISTRIBUTION AND EXCRETION OF ANTINEOPLASTIC DRUGS. | |
| 505 | 8 | |a Operational cytokinetics of bone marrow and intestineDescriptive cytokinetics of tumors; Operational cytokinetics of tumors; Comparison between the descriptive and operational approaches to cytokinetics; C O N C L U S I O N S; REFERENCES; CHAPTER 8. ROLE OF ENZYMATIC ACTIVATION AND INACTIVATION IN DRUG SELECTIVITY; Purine and pyrimidine antimetabolites; Cyclophosphamide and dimethyl-triazeno-imidazole carboxamide; Other drugs inactivated in insensitive tissues; Inactivation followed by reactivation; CONCLUSIONS; REFERENCES. | |
| 505 | 8 | |a CHAPTER 9. GENERAL MECHANISMS OF CLINICAL RESISTANCE TO CANCER CHEMOTHERAPYREFERENCES; CHAPTER 10. MECHANISMS OF CLINICAL DRUG RESISTANCE TO ALKYLATING AGENTS; CLASSES OF ALKYLATING AGENT AND MECHANISM OF ACTION; DEFINITION OF RESISTANCE; CONCLUSIONS; REFERENCES; CHAPTER 11. RESISTANCE TO FOLIC ACID ANTAGONISTS -CLINICAL ASPECTS; General considerations; Resistance to MTX in experimental tumors; Resistance to MTX in man; Prevention and exploitation of folate antagonist resistance; REFERENCES; CHAPTER 12. RESISTANCE TO PURINE ANALOGS; CONCLUSIONS; REFERENCES. | |
| 505 | 8 | |a CHAPTER 13. CLINICAL RESISTANCE TO ANTIPYRIMIDINE ANTICANCER DRUGSFluorouracil; Clinical pharmacologic attacks on pyrimidine-resistant tumors; REFERENCES; CHAPTER 14. BIOCHEMICAL AND PHARMACOLOGICAL PRINCIPLES OF COMBINATION CHEMOTHERAPY; REFERENCES; CHAPTER 15. THERAPEUTIC SYNERGISM IN ANIMAL MODELS -- INCREASED ANTITUMOR SPECIFICITY RESULTING FROM DIMINISHED TOXICITY FOR THE HOST; REFERENCES; CHAPTER 16. SCHEDULE-DEPENDENT SYNERGISM AND ANTAGONISM BETWEEN METHOTREXATE AND ASPARAGINASE; METHODS AND MATERIALS; RESULTS; DISCUSSION; REFERENCES. | |
| 520 | |a Symposium on Clinical Pharmacology reviews advances in clinical pharmacology, with emphasis on how to materially improve the efficacy of cancer chemotherapy. Topics range from absorption, protein binding, distribution, and excretion of antineoplastic drugs to factors affecting the biotransformation and activity of antitumor drugs. The transport of tumor-inhibitory agents across cell membranes is also examined, together with factors influencing drug selectivity and the mechanisms of clinical drug resistance. This volume is comprised of 23 chapters and begins with a brief summary of the differen. | ||
| 650 | 0 | |a Cancer |x Chemotherapy |v Congresses. | |
| 650 | 0 | |a Cancer |x Chemotherapy |x Congresses. | |
| 650 | 0 | |a Pharmacology |x Congresses. | |
| 650 | 2 | |a Antineoplastic Agents |x pharmacology |0 (DNLM)D000970Q000494 | |
| 650 | 2 | |a Antineoplastic Agents |x therapeutic use |0 (DNLM)D000970Q000627 | |
| 650 | 6 | |a Cancer |0 (CaQQLa)201-0004691 |x Chimioth�erapie |0 (CaQQLa)201-0004691 |x Congr�es. |0 (CaQQLa)201-0378208 | |
| 650 | 6 | |a Anticanc�ereux |0 (CaQQLa)201-0004692 |x Pharmacodynamie |x Congr�es. |0 (CaQQLa)201-0378208 | |
| 650 | 6 | |a Pharmacologie |0 (CaQQLa)201-0007219 |x Congr�es. |0 (CaQQLa)201-0378208 | |
| 650 | 6 | |a Cancer |0 (CaQQLa)201-0004691 |x Chimioth�erapie |0 (CaQQLa)201-0004691 |v Congr�es. |0 (CaQQLa)201-0378219 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Pharmacology |2 fast |0 (OCoLC)fst01060259 | |
| 650 | 7 | |a Cancer |x Chemotherapy |2 fast |0 (OCoLC)fst00845327 | |
| 655 | 2 | |a Congress |0 (DNLM)D016423 | |
| 655 | 7 | |a proceedings (reports) |2 aat |0 (CStmoGRI)aatgf300027316 | |
| 655 | 7 | |a Conference papers and proceedings |2 fast |0 (OCoLC)fst01423772 | |
| 655 | 7 | |a Conference papers and proceedings. |2 lcgft | |
| 655 | 7 | |a Actes de congr�es. |2 rvmgf |0 (CaQQLa)RVMGF-000001049 | |
| 700 | 1 | |a Creasey, William A., |e editor. | |
| 700 | 1 | |a Lane, Montague, |e editor. | |
| 700 | 1 | |a Sartorelli, Alan C., |e editor. | |
| 710 | 2 | |a National Cancer Institute (U.S.). |b Cancer Clinical Investigation Review Committee. | |
| 776 | 0 | 8 | |i Print version: |a Symposium on Clinical Pharmacology (1973 : Jacksonville, Fla.). |t Symposium on Clinical Pharmacology. |d New York : Pergamon Press, 1975 |w (DLC) 74031005 |w (OCoLC)2569979 |
| 830 | 0 | |a Biochemical pharmacology : Supplement ; |v 1974, no. 2. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780080189499 |z Texto completo |